CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 282 enrolled
Drug / intervention
Neuromuscular Blocking Agentsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04028362
NCT04028362N/ACompleted

Neuromuscular Blockade in the Intentive Care Unit, an Observational Study.

French Society for Intensive Care·observational·Posted Jul 22, 2019·Updated Dec 16, 2021

In Brief

An observational study evaluating Neuromuscular Blocking Agents for Critical Care and 2 related conditions. Completed, enrolled 282 participants across 11 sites.

Detailed Summary

The study Short description of the protocol intended for the lay public. Include a brief statement of the study hypothesis. (Limit: 5000 characters) Neuromuscular blocking agents (NMBAs) are drug capable of inducing a complete paralysis of the muscle. Their use is frequent in the intensive care unit (ICU). Most of the time it is used as a single infusion to facilitate endotracheal intubation, but in the ICU the use of continuous infusion is common in several pathologies: acute distress respiratory syndrome, post-cardiac arrest survivor under hypothermia to prevent shivering, abdominal compartment syndrome, severe traumatic brain injury with uncontrolled intra-cranial pressure and severe asthma among others. A monitoring of the dose of NMBAs is recommended to guide the depth of paralysis and to guide recovery, but in the ICU, the interest of such a monitoring during continuous infusion is unclear and the level of evidence is low. The investigators propose to conduct a prospective multicentric observational study to describe the current practice in the use of NMBAs in mechanically ventilated patients in the ICU. As a primary objective we will describe the prevalence of NMBAs use in the ICU. As a secondary objective, the investigators will investigate the impact of protocol and/or monitoring devices of NMBAs on the dose administered and clinical outcome endpoints.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 22, 2019
Enrollment StartNov 2, 2019
Primary CompletionApr 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.9 years ago

Interventions

Neuromuscular Blocking Agentsdrug

Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.